Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
BgRT + SBRT + Osimertinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial tests how well BgRT and SBRT with osimertinib work to treat EGFR+ lung cancer that has spread from the primary site. BgRT & SBRT target active tumors, osimertinib blocks the protein that signals cancer cells to multiply, potentially killing more tumor cells.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service